Evidence map›Paper›PMID 23874157›Full record

ArticlePLoS biology2013

Production of α-galactosylceramide by a prominent member of the human gut microbiota.

Laura C Wieland Brown, Cristina Penaranda, Purna C Kashyap, Brianna B Williams, Jon Clardy, Mitchell Kronenberg, Justin L Sonnenburg, Laurie E Comstock, Jeffrey A Bluestone, Michael A Fischbach

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers.

0numbers the graph read from it
0cells of the map it votes in
161citing papers in PubMed
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

161 citing papers in PubMed, 247 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Novel Genomes ofMicroorganisms · 2026
    Article
  6. Review
  7. Article
  8. Decoding the power of the microbiome in human health.Frontiers in cellular and infection microbiology · 2026
    Review
  9. Human gut commensalGut microbes · 2025
    Article
  10. Review
  11. Review
  12. Metabolites · 2025
    Article
  13. Article
  14. The α glycolipid rules the NKT cell TCR.The Journal of experimental medicine · 2025
    Article
  15. Iron limitation triggers roseoceramide biosynthesis and membrane remodeling in marine roseobacter.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

101 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Laura C Wieland BrownDepartment of Bioengineering and Therapeutic Sciences and the California Institute for Quantitative Biosciences, University of California, San Francisco, California, United States of America.
Cristina Penaranda
Purna C Kashyap
Brianna B Williams
Jon Clardy
Mitchell Kronenberg
Justin L Sonnenburg
Laurie E Comstock
Jeffrey A Bluestone
Michael A Fischbach
University of California, San Francisco · USHarvard University · USStanford University · USLa Jolla Institute for Immunology · USQB3 · US

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCMANUS, MICHAEL T · 2003 to 2019
$21.8M
Molecule-to-gene approaches to new natural productsR01GM086258 · NIGMS · HARVARD MEDICAL SCHOOL · PI CLARDY, JON · 2008 to 2016
$3.6M
Recognition of bacterial antigens by NKT cellsR01AI045053 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI KRONENBERG, MITCHELL · 2000 to 2010
$3.3M
Regulation of the multiple polysaccharides of Bacteroides fragilisR01AI044193 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI COMSTOCK, LAURIE E · 1999 to 2010
$2.7M
IMMUNOMODULATION OF TRANSPLANT REJECTION BY ANTI-CD3 MABR37AI046643 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BLUESTONE, JEFFREY A · 2000 to 2009
$2.5M
Identifying and characterizing small molecules from the human microbiomeDP2OD007290 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FISCHBACH, MICHAEL ANDREW · 2010 to 2010
$2.3M
NIAID NIH HHS R01 AI044193NIAID NIH HHS R01 AI045053NIAID NIH HHS R01 AI45053NIAID NIH HHS R37 AI046643NIAID NIH HHS R37 AI46643NIDDK NIH HHS P30 DK063720NIDDK NIH HHS P30 DK63720NIGMS NIH HHS R01 GM086258NIH HHS DP2 OD007290
6 · The paper itself

Abstract

While the human gut microbiota are suspected to produce diffusible small molecules that modulate host signaling pathways, few of these molecules have been identified. Species of Bacteroides and their relatives, which often comprise >50% of the gut community, are unusual among bacteria in that their membrane is rich in sphingolipids, a class of signaling molecules that play a key role in inducing apoptosis and modulating the host immune response. Although known for more than three decades, the full repertoire of Bacteroides sphingolipids has not been defined. Here, we use a combination of genetics and chemistry to identify the sphingolipids produced by Bacteroides fragilis NCTC 9343. We constructed a deletion mutant of BF2461, a putative serine palmitoyltransferase whose yeast homolog catalyzes the committed step in sphingolipid biosynthesis. We show that the Δ2461 mutant is sphingolipid deficient, enabling us to purify and solve the structures of three alkaline-stable lipids present in the wild-type strain but absent from the mutant. The first compound was the known sphingolipid ceramide phosphorylethanolamine, and the second was its corresponding dihydroceramide base. Unexpectedly, the third compound was the glycosphingolipid α-galactosylceramide (α-GalCer(Bf)), which is structurally related to a sponge-derived sphingolipid (α-GalCer, KRN7000) that is the prototypical agonist of CD1d-restricted natural killer T (iNKT) cells. We demonstrate that α-GalCer(Bf) has similar immunological properties to KRN7000: it binds to CD1d and activates both mouse and human iNKT cells both in vitro and in vivo. Thus, our study reveals BF2461 as the first known member of the Bacteroides sphingolipid pathway, and it indicates that the committed steps of the Bacteroides and eukaryotic sphingolipid pathways are identical. Moreover, our data suggest that some Bacteroides sphingolipids might influence host immune homeostasis.

Indexed as

AnimalsBacteroides fragilisCells, CulturedGalactosylceramidesHumansMiceMutationNatural Killer T-Cellsalpha-galactosylceramideGalactosylceramides

Identifiers

PMID23874157
PMCPMC3712910
OpenAlexW2060616011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.